Table 1.
The clinic manifestations and baseline characteristics of anti-NMDAR encephalitis VM and controls.
| NMDAR (n = 25) | VM (n = 12) | Control (n = 26) | |
|---|---|---|---|
| Gender (male/female) | 11/14 | 7/5 | 13/13 |
| Age (years) | 35.5 ± 19.7 | 34.5 ± 15.8 | 38.8 ± 16.2 |
| Psychiatric and neurologic symptoms | |||
| Fever | 14 (56%) | 8 (67%) | – |
| Disorders of memory, behavior, and cognition | 22 (88%) | 4 (33%)*** | – |
| Seizures | 18 (72%) | 3 (25%)** | – |
| Autonomic disturbances | 10 (40%) | 2 (17%) | – |
| Disturbance of consciousness | 15 (60%) | 6 (50%) | – |
| Abnormal movements | 11 (44%) | 2 (17%) | – |
| ovarian teratoma | 3 (12%) | 0 (0%) | – |
| CSF white blood cell count ( × 106/L, median) | 4(1,18) | 3 (0.58) | 0 (0, 0)*** |
| CSF protein(g/L, median) | 0.30 (0.17, 0.76) | 0.25 (0.18, 0.94) | 0.28 (0.19, 0.40) |
| Maximum mRS scores | 4, (4,5) | - | - |
| 6 months' mRS scores after the disease onset | 3, (2,3) | - | - |
| Anti-NMDAR antibody | 25 | 0 | 0 |
**
p < 0.01,
***
p < 0.001.